1.64
Palisade Bio Inc (PALI) 最新ニュース
Treasury Yields: Will Palisade Bio Inc benefit from current market trends2025 Winners & Losers & Community Consensus Trade Signals - baoquankhu1.vn
PALI SEC FilingsPalisade Bio Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Short Interest in Palisade Bio, Inc. (NASDAQ:PALI) Rises By 20.2% - MarketBeat
Palisade Bio Announces Participation in Two Upcoming Investor Conferences - Bitget
Palisade Bio Details PALI-2108 UC, Crohn’s Plans and Cash Runway Into 2029 at Oppenheimer Conference - MarketBeat
Palisade Bio (NASDAQ:PALI) Upgraded to "Hold" at Wall Street Zen - MarketBeat
PALI Should I Buy - Intellectia AI
PALI: Advancing a once-daily, gut-restricted PDE4 inhibitor with strong funding and pivotal trials ahead - TradingView
Palisade Bio (NASDAQ:PALI) Now Covered by Stifel Nicolaus - MarketBeat
Stifel Initiates Palisade Bio at Buy With $5 Price Target - marketscreener.com
This Alumis Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Benzinga
Palisade Bio (PALI) Sees New 'Buy' Rating from Stifel | PALI Sto - GuruFocus
Stifel Initiates Coverage of Palisade Bio (PALI) with Buy Recommendation - Nasdaq
Stifel initiates Palisade Bio stock with buy rating on IBD drug - Investing.com South Africa
PALI Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Stifel initiates Palisade Bio stock with buy rating on IBD drug By Investing.com - Investing.com Canada
Palisade Bio Strengthens Advisory Board, Fast-tracks Key Research Developments - timothysykes.com
Palisade Bio presents ulcerative colitis drug trial data at ECCO By Investing.com - Investing.com India
Palisade Bio presents ulcerative colitis drug trial data at ECCO - Investing.com
Palisade Bio, Inc. Presents Phase 1b Data Demonstrating Localized Target Engagement and Early Clinical Response of PALI-2108 in Ulcerative Colitis at ECCO 2026 - Quiver Quantitative
Palisade Bio Reports Rapid Clinical, Histologic and New Mechanistic Colon Tissue RNA Sequencing Data Supporting Targeted Activity of PALI-2108 at ECCO 2026 - Bitget
Palisade Bio Reports Rapid Clinical, Histologic and New - GlobeNewswire
Palisade Bio, Inc. (NASDAQ:PALI) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
Palisade Bio, Inc. (NASDAQ:PALI) Sees Large Increase in Short Interest - Defense World
Palisade Bio appoints IBD expert to clinical advisory board By Investing.com - Investing.com Canada
Perceptive fund discloses 9.99% Palisade Bio (PALI) ownership stake - Stock Titan
Palisade Bio appoints IBD expert to clinical advisory board - Investing.com
Palisade Bio Appoints Global IBD Precision Medicine Leader Bram Verstockt, MD, PhD to Clinical Advisory Board - Bitget
Palisade Bio Strengthens Clinical Advisory Board with Appointment of Dr. Bram Verstockt to Advance PALI-2108 Development in Ulcerative Colitis and Crohn's Disease - Quiver Quantitative
Ulcerative colitis drug PALI-2108 gets boost from new IBD advisor - Stock Titan
Palisade Bio (PALI) chief medical officer Jones sells $3480 in stock - Investing.com UK
Can Palisade Bio Inc. (7NS0) stock resist broad market declinesPortfolio Risk Report & Precise Trade Entry Recommendations - mfd.ru
Palisade Bio (PALI) chief medical officer Jones sells $3480 in stock By Investing.com - Investing.com Australia
Palisade Bio CEO Finley sells $6818 in shares - Investing.com South Africa
Palisade Bio CEO Finley sells $6818 in shares By Investing.com - Investing.com India
Palisade Bio Inc. (PALI) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Can Palisade Bio Inc. maintain sales growthJuly 2025 Chart Watch & Accurate Buy Signal Notifications - mfd.ru
Palisade Bio (PALI) awards Chief Medical Officer 787,000 RSUs - Stock Titan
Palisade Bio to Participate in the Piper Sandler Virtual Novel Targets in Immunology Symposium - GlobeNewswire
Biotech Palisade Bio joins Piper Sandler talk on new immune targets - Stock Titan
Palisade Bio (NASDAQ:PALI) Lowered to Sell Rating by Wall Street Zen - MarketBeat
Aug Shorts: Will Palisade Bio Inc outperform its industry peers2025 Retail Activity & Free Growth Oriented Trading Recommendations - baoquankhu1.vn
Aug Sentiment: Is Palisade Bio Inc stock a good pick for beginners2025 Volume Leaders & Safe Capital Investment Plans - baoquankhu1.vn
Palisade Bio to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference - marketscreener.com
Palisade Bio leaders set for virtual Oppenheimer healthcare conference slot - Stock Titan
Franklin Resources Inc's Strategic Acquisition of Palisade Bio I - GuruFocus
Palisade Bio (PALI) soars 5% ahead of clinical trial results - MSN
Can Palisade Bio Inc maintain sales growth2025 Sector Review & Free Expert Approved Momentum Trade Ideas - baoquankhu1.vn
Palisade Bio (PALI) upgraded to buy: Here's what you should know - MSN
Palisade Bio appoints two IBD experts to clinical advisory board By Investing.com - Investing.com South Africa
大文字化:
|
ボリューム (24 時間):